Altered Staining Patterns and Expression Level of Engrailed-2 in Benign Prostatic Hyperplasia and Prostate Cancer Predict Prostatic Disease Progression

Overview

Journal BMC Cancer

Publisher Biomed Central

Specialty Oncology

Date 2020 Jun 17

PMID 32539763

Citations 1

Authors

Qi Li

Yibo Shi

Rigai Sa

Jun Hao

Jinhao Hu

Mulun Xiao

Chaoliang Wang

Liang Yan

Baoping Qiao

Guoxun Chen

Affiliations

Soon will be listed here.

Abstract

Background: Prostate cancer (PC), a common malignant tumor, is the second-leading cause of cancer death among American men. Its successful treatment greatly relies on the early diagnose. Engrailed-2 (EN2) has been confirmed being existed with a high level in the urine of PC patients. In this study, to explore the application of EN2 in PC, we detected the immunohistochemical staining difference and EN2 expression level between benign prostatic hyperplasia (BPH) and PC.

Methods: We developed a monoclonal antibody against the helix 3 in EN2 and confirmed its specificity with Western blotting (WB) and immunofluorescence detecting the subcellular localization of endogenous and exogenous EN2 in three PC cell lines (LNCap, PC3, and DU145). We conducted immunohistochemical staining using this homemade antibody, and RT-PCR to detect the expression of EN2 in 25 PC and 25 BPH cases, and analyzed the correlation of EN2 expression and PC clinical staging.

Results: The results of WB and immunofluorescence showed our homemade EN2 monoclonal antibody could specifically bind endogenous and exogenous EN2 protein in three different PC cell lines. Endogenous EN2 was generally expressed in the cytoplasm and exogenous EN2 mostly existed in the nucleus of these cell lines. Immunohistochemical staining in PC had extremely stronger signals than that in BPH, suggesting a higher EN2 expression level in PC, which was confirmed by RT-PCR. Interestingly, the stained areas in BPH tissues were mainly in nucleus and cytoplasm, while in PC tissues were mainly on cytomembrane. Moreover, the expression level of EN2 was positively correlated with the PC clinical staging.

Conclusion: Using our homemade EN2 antibody, we have found different staining patterns and expression level of EN2 in BPH and PC,which may be helpful to predict prostatic disease progression.

Citing Articles

Effect of Bicalutamide Combined with Docetaxel on Serum PSA and VEGF Levels in Patients with Advanced Prostate Carcinoma.

Guo Z, Hu X, Lv R, Zhang Y, Meng L, Liu Z Dis Markers. 2022; 2022:4506350.

PMID: 36033830 PMC: 9402358. DOI: 10.1155/2022/4506350.

References

Andriole G, Crawford E, Grubb 3rd R, Buys S, Chia D, Church T . Mortality results from a randomized prostate-cancer screening trial. N Engl J Med. 2009; 360(13):1310-9. PMC: 2944770. DOI: 10.1056/NEJMoa0810696. View

Joliot A, Maizel A, Rosenberg D, Trembleau A, Dupas S, Volovitch M . Identification of a signal sequence necessary for the unconventional secretion of Engrailed homeoprotein. Curr Biol. 1998; 8(15):856-63. DOI: 10.1016/s0960-9822(07)00346-6. View

Scaccianoce E, Festuccia C, Dondi D, Guerini V, Bologna M, Motta M . Characterization of prostate cancer DU145 cells expressing the recombinant androgen receptor. Oncol Res. 2003; 14(2):101-12. DOI: 10.3727/000000003108748658. View

Li J, Lai Y, Cao Y, Du T, Zeng L, Wang G . SHARPIN overexpression induces tumorigenesis in human prostate cancer LNCaP, DU145 and PC-3 cells via NF-κB/ERK/Akt signaling pathway. Med Oncol. 2015; 32(2):444. DOI: 10.1007/s12032-014-0444-3. View

Carlier L, Balayssac S, Cantrelle F, Khemtemourian L, Chassaing G, Joliot A . Investigation of homeodomain membrane translocation properties: insights from the structure determination of engrailed-2 homeodomain in aqueous and membrane-mimetic environments. Biophys J. 2013; 105(3):667-78. PMC: 3738247. DOI: 10.1016/j.bpj.2013.06.024. View

Pandha H, Sorensen K, Orntoft T, Langley S, Hoyer S, Borre M . Urinary engrailed-2 (EN2) levels predict tumour volume in men undergoing radical prostatectomy for prostate cancer. BJU Int. 2012; 110(6 Pt B):E287-92. DOI: 10.1111/j.1464-410X.2012.11208.x. View

Lai C, Xu Y, Yu G, Wu X, Li Y, Pan B . Engrailed-2 might play an anti-oncogenic role in clear-cell renal cell carcinoma. J Mol Histol. 2016; 47(3):229-37. DOI: 10.1007/s10735-016-9665-4. View

Dai X, Fang X, Ma Y, Xianyu J . Benign Prostatic Hyperplasia and the Risk of Prostate Cancer and Bladder Cancer: A Meta-Analysis of Observational Studies. Medicine (Baltimore). 2016; 95(18):e3493. PMC: 4863764. DOI: 10.1097/MD.0000000000003493. View

Grozescu T, Popa F . Prostate cancer between prognosis and adequate/proper therapy. J Med Life. 2017; 10(1):5-12. PMC: 5304372. View

10.

Wallis C, Saskin R, Choo R, Herschorn S, Kodama R, Satkunasivam R . Surgery Versus Radiotherapy for Clinically-localized Prostate Cancer: A Systematic Review and Meta-analysis. Eur Urol. 2015; 70(1):21-30. DOI: 10.1016/j.eururo.2015.11.010. View

11.

Watanabe A, Harimoto N, Araki K, Kubo N, Igarashi T, Tsukagoshi M . Absolute Neutrophil Count Predicts Postoperative Prognosis in Mass-forming Intrahepatic Cholangiocarcinoma. Anticancer Res. 2019; 39(2):941-947. DOI: 10.21873/anticanres.13197. View

12.

Punia N, Primon M, Simpson G, Pandha H, Morgan R . Membrane insertion and secretion of the Engrailed-2 (EN2) transcription factor by prostate cancer cells may induce antiviral activity in the stroma. Sci Rep. 2019; 9(1):5138. PMC: 6435720. DOI: 10.1038/s41598-019-41678-0. View

13.

McGrath S, Annels N, Madhuri T, Tailor A, Butler-Manuel S, Morgan R . Engrailed-2 (EN2) - a novel biomarker in epithelial ovarian cancer. BMC Cancer. 2018; 18(1):943. PMC: 6171236. DOI: 10.1186/s12885-018-4816-5. View

14.

Mokhtari M, Homayoun M, Yazdan Panah S . The Prevalence of Prostatic Stromal Tumor of Uncertain Malignant Potential in Specimens Diagnosed as Prostatic Hyperplasia. Arch Iran Med. 2016; 19(7):488-90. DOI: 0161907/AIM.007. View

15.

Kim J, Bae J . Tumor-Associated Macrophages and Neutrophils in Tumor Microenvironment. Mediators Inflamm. 2016; 2016:6058147. PMC: 4757693. DOI: 10.1155/2016/6058147. View

16.

Altuwaijri S, Wu C, Niu Y, Mizokami A, Chang H, Chang C . Expression of human AR cDNA driven by its own promoter results in mild promotion, but not suppression, of growth in human prostate cancer PC-3 cells. Asian J Androl. 2007; 9(2):181-8. DOI: 10.1111/j.1745-7262.2007.00258.x. View

17.

Morgan R, El-Tanani M, Hunter K, Harrington K, Pandha H . Targeting HOX/PBX dimers in cancer. Oncotarget. 2017; 8(19):32322-32331. PMC: 5458287. DOI: 10.18632/oncotarget.15971. View

18.

Sebesta E, Anderson C . The Surgical Management of Prostate Cancer. Semin Oncol. 2018; 44(5):347-357. DOI: 10.1053/j.seminoncol.2018.01.003. View

19.

McGrath S, Michael A, Morgan R, Pandha H . EN2 in Prostate Cancer. Adv Clin Chem. 2015; 71:47-76. DOI: 10.1016/bs.acc.2015.06.002. View

20.

Logan C, Hanks M, Nallainathan D, Provart N, Joyner A . Cloning and sequence comparison of the mouse, human, and chicken engrailed genes reveal potential functional domains and regulatory regions. Dev Genet. 1992; 13(5):345-58. DOI: 10.1002/dvg.1020130505. View